Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thermo Fisher Scientific has reported that its Maybridge Ro3 Diversity Fragment Library was successfully used by the researchers to validate an emerging technique for drug discovery that targets key protein receptors involved in a wide range of biological functions.
Subscribe to our email newsletter
For the study, David Myszka, founder of Biosensor Tools and director of the Center for Biomolecular Interaction Analysis at the University of Utah, used surface plasmon resonance (SPR) to screen fragments in the Maybridge Ro3 collection against stabilised G-Protein Coupled Receptors (GPCRs) provided by Heptares Therapeutics1.
Several new classes of compounds were detected from the Ro3 library, which are accelerating drug discovery efforts around these receptors.
Using the follow-up studies, Thermo Fisher Scientific is now planning to pursue the next stage in elaborating compounds for drug development.
Myszka said while fragment screening by SPR has become standard practice, this is the first example of a successful SPR-based fragment screen against GPCRs.
"One major factor contributing to our success was the integrity of the Maybridge Ro3 Fragments, " Myszka said.